Development | Plasmid-Based Preparations | Plasmid-Based Analgesic
Plasmid-Based Analgesic
We have developed innovative plasmid DNA-based analgesic constructs featuring two distinct variants:

• Encoding human defensin peptides
• Encoding engineered beta-endorphin. The beta-endorphin plasmid incorporates several key modifications including receptor-tropism enhancing mutations, a potent heterologous secretory sequence, and a TLR9-binding domain that significantly improves cellular transfection efficiency.

The prolonged analgesic effect is achieved through multiple mechanisms:

• The plasmid DNA serves as a template for sustained in vivo protein production
• Incorporated mRNA-stabilizing elements extend mRNA half-life and increase translational efficiency, allowing more protein to be synthesized from each mRNA molecule
• The codon-optimized nucleotide sequence ensures highly efficient expression in mammalian cellsе.

This advanced design enables a dramatic 10-50 fold reduction in required plasmid DNA dosage compared to current gene therapy practices.

The enhanced safety profile stems from several inherent properties:

• The plasmid DNA remains episomal without genomic integration, directing the synthesis and secretion of natural human proteins in their native form, thereby avoiding immunogenic reactions.
• The expressed proteins undergo complete physiological processing including proper post-translational modifications and chaperone-mediated folding, while being metabolized through natural pathways without generating toxic byproducts.
• As the plasmid doesn't replicate in mammalian cells, it provides precise control over both protein production levels and consequent analgesic effects.
• This DNA-based analgesic offers flexible administration options, being suitable for both localized delivery and systemic administration, while maintaining all the advantages of endogenous protein production with none of the risks associated with conventional gene therapy approaches.

The combination of extended duration, superior safety, and dosing flexibility positions this technology as a groundbreaking advancement in pain management therapeutics.